Friday, July 10, 2026

pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia

Elan Pharmaceuticals

Elan Pharmaceuticals trial registry — 18 ClinicalTrials.gov studies with program phase, status, and indication context.

Treasury Building, Lower Grand Canal Street, Dublin 2, IE HQ
1969 Founded
792 Employees
EMA registrant Type
Company details
Status
Public
HQ
Treasury Building, Lower Grand Canal Street, Dublin 2, IE
Founded
1969
Employees
792
Programs
18
Drugs
26
Patents
0
Intelligence · Clinical Trials

Elan Pharmaceuticals clinical trials

Registry index of 18 ClinicalTrials.gov studies linked to Elan Pharmaceuticals programs — each row shows trial ID, program name, phase, status, and indication.

Elan Pharmaceuticals trial registry — 18 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Elan Pharmaceuticals.

  1. HZNP-DAX-202 — Phase 2

    Clinical update
  2. VIB0551.P3.S2 — Phase 3

    Clinical update
  3. VIB0551.P3.S1 — Phase 3

    Clinical update
  4. HZNP-HZN-825-303 — Phase 2

    Clinical update
  5. HZNP-DAZ-301 — Phase 3

    Clinical update
  6. OCUS-Mode-CT-V1 — Phase 3

    Clinical update
  7. HZNP-HZN-825-301 — Phase 2

    Clinical update
  8. HZNP-HZN-1116-201 — Phase 2

    Clinical update

Trial registry

18 studies
  1. 2023-510007-22-00

    INEBILIZUMAB

    Phase 2 active small_molecule

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    CTIS ↗